Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tiotropium
Drug: BI 54903

First Posted Date: 2011-03-04

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT01309139

Locations: 🇩🇪
1298.2.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

SMS Reminder to Assess Adherence

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Procedure: SMS reminder
Procedure: control group

First Posted Date: 2011-03-04

Last Posted Date: 2013-01-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 95

Registration Number: NCT01308476

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site 3, Hamburg, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 1, Berlin, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 5, Lübeck, Germany

and more 2 locations

Drug Interaction Study of Digoxin and BI 10773

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Digoxin plus BI 10773
Drug: Digoxin

First Posted Date: 2011-03-01

Last Posted Date: 2014-06-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT01306175

Locations: 🇩🇪
1245.40.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Obesity

Interventions: Drug: Placebo
Drug: BI 10773

First Posted Date: 2011-03-01

Last Posted Date: 2014-06-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 566

Registration Number: NCT01306214

Locations: 🇺🇸
1245.49.10019 Boehringer Ingelheim Investigational Site, Westlake Village, California, United States
🇺🇸
1245.49.10007 Boehringer Ingelheim Investigational Site, Fargo, North Dakota, United States
🇺🇸
1245.49.10015 Boehringer Ingelheim Investigational Site, Evansville, Indiana, United States

and more 100 locations

Drug Interaction Study With Dabigatran Etexilate and Dronedarone in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran etexilate
Drug: Dabigatran etexilate plus dronedarone

First Posted Date: 2011-03-01

Last Posted Date: 2014-06-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT01306162

Locations: 🇩🇪
1160.112.1 Boehringer Ingelheim Investigational Site, Ulm, Germany

Drug-drug Interaction of Empagliflozin (BI 10773) and Simvastatin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773
Drug: simvastatin

First Posted Date: 2011-02-25

Last Posted Date: 2014-07-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT01304329

Locations: 🇩🇪
1245.63.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Aggrenox and omeprazole
Drug: Omeprazole alone
Drug: Aggrenox alone

First Posted Date: 2011-02-24

Last Posted Date: 2013-12-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT01303445

Locations: 🇺🇸
9.197.001 Boehringer Ingelheim Investigational Site, Tempe, Arizona, United States

Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773
Drug: Gemfibrozil

First Posted Date: 2011-02-23

Last Posted Date: 2014-06-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT01301742

Locations: 🇩🇪
1245.58.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib

Phase 1

Completed

Conditions: Healthy
Liver Diseases

Interventions: Drug: Afatinib

First Posted Date: 2011-02-17

Last Posted Date: 2013-12-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 35

Registration Number: NCT01298063

Locations: 🇩🇪
1200.86.1 Boehringer Ingelheim Investigational Site, Kiel, Germany

BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)

Phase 1

Completed

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Drug: BI 836826

First Posted Date: 2011-02-16

Last Posted Date: 2020-08-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 37

Registration Number: NCT01296932

Locations: 🇧🇪
UNIV UZ Gent, Gent, Belgium
🇫🇷
CTR Investigation Clinique, onco, Montpellier, Montpellier Cedex 5, France
🇫🇷
INS Universitaire du Cancer, Toulouse, France

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy